Detalles de la búsqueda
1.
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
Strahlenther Onkol
; 2023 Nov 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37975883
2.
Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.
Eur J Nucl Med Mol Imaging
; 50(8): 2466-2476, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36951991
3.
Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.
Cancer
; 128(12): 2358-2366, 2022 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35417563
4.
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Invest New Drugs
; 40(1): 163-171, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34351518
5.
Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
Eur J Nucl Med Mol Imaging
; 49(4): 1407-1416, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34664091
6.
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
Invest New Drugs
; 39(4): 1189-1196, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33704621
7.
External Validation of a Survival Score for Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy.
Lung
; 198(1): 201-206, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31897594
8.
Correction to: Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
Strahlenther Onkol
; 194(4): 363-364, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29541791
9.
Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
Strahlenther Onkol
; 194(2): 107-115, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29116336
10.
How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience.
Eur J Nucl Med Mol Imaging
; 45(12): 2103-2109, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29876620
11.
Feasibility of hypofractionated radiotherapy in inoperable node-positive NSCLC patients with poor prognostic factors and limited pulmonary reserve: a prospective observational study.
Acta Oncol
; 60(8): 1074-1078, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34155956
12.
Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.
J Cancer Res Clin Oncol
; 149(7): 3267-3276, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35915184
13.
Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports.
Expert Opin Investig Drugs
; 32(3): 187-200, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36780358
14.
Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
J Cancer Res Clin Oncol
; 149(10): 7393-7403, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36939927
15.
PET/CT for Target Delineation of Lung Cancer Before Radiation Therapy.
Semin Nucl Med
; 52(6): 673-680, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35781392
16.
Radiation-Induced Lung Injury: Prevention, Diagnostics and Therapy in the Era of the COVID-19 Pandemic.
J Clin Med
; 11(19)2022 Sep 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36233578
17.
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study.
Transl Lung Cancer Res
; 11(7): 1503-1509, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35958344
18.
Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer-A Prospective Longitudinal Assessment.
Diagnostics (Basel)
; 11(11)2021 Oct 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34829315
19.
Prognostic Role of Lung Immune Scores for Prediction of Survival in Limited-stage Small Cell Lung Cancer.
In Vivo
; 35(2): 929-935, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33622885
20.
Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting.
Cancers (Basel)
; 13(7)2021 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-33807324